Mosaic ImmunoEngineering is a nanotechnology-based immunotherapy company developing therapeutics and vaccines to positively impact the lives of patients and their families.

Free
Message: The 336 merged reexam decision

The USPTO has been reviewing the patents during the early licensing process. How did TPL get any companies to pony up for a license in the past? What has changed from a year ago that would put a halt on the licenses?

Is the answer simply that the cost of a license has gone up to a level that remaining companies are doing what you suggest or is there something else that has changed?

All the best,

Steve

Share
New Message
Please login to post a reply